FDA Eases Requirements for CAR T-Cell Therapies

The FDA exempted chimeric antigen receptor (CAR) T-cell therapies from REMS and loosened restrictions on patients after receiving the treatment. Experts say a much-improved ability to manage the side effects of CAR T-cell therapies supports the decision, making it easier for patients to access these therapies.

Publication Details

Journal
Cancer Discovery
Published
2025-01-01
DOI
https://doi.org/10.1158/2159-8290.cd-nw2025-0063
Primary Topic
Biomedical Ethics and Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FDA Eases Requirements for CAR T-Cell Therapies

Cancer Discovery
Biomedical Ethics and Regulation
article

FDA Eases Requirements for CAR T-Cell Therapies

article en

Abstract

The FDA exempted chimeric antigen receptor (CAR) T-cell therapies from REMS and loosened restrictions on patients after receiving the treatment. Experts say a much-improved ability to manage the side effects of CAR T-cell therapies supports the decision, making it easier for patients to access these therapies.

Cancer Discovery
Openalex Percentile: Top 76%
Biomedical Ethics and Regulation
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

FDA Eases Requirements for CAR T-Cell Therapies · Cancer Discovery (2025) | TGRS Research Map | TGRS